A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portion

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000053-30

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Determine whether the overall survival of the combination of AG-013736 and gemcitabine is superior to that of gemcitabine alone in patients who have advanced pancreatic cancer that has not been previously treated with systemic therapy.


Critère d'inclusion

  • Treatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreas